Navigation Links
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human antibody drug discovery company with world class expertise in targeting multi-spanning membrane proteins, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.

Under the terms of the agreement, Debiopharm and MSM haveformed a partnership to select antibodies against the GPCR. Upon completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody. MSM will retain marketing rights for Russia, Ukraine and several other countries in Eastern Europe and Asia. MSM will receive milestone payments from Debiopharm during the development of the product, as well as a share of royalties on net sales.

"We usually licence-in compounds with existing animal proof of concept, but we were seduced by MSM's technology and their expertise in the generation of antibodies aimed at GPCRs," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "This is a win-win situation, our companies complement one another. MSMs discovery expertise, together with our experience in drug development should lead to innovative oncology therapeutics."

"This is a transformational deal for MSM because it represents our first jointly owned program with a global partner. We are pleased to be working with Debiopharm because they are an excellent company that complements MSM's skill set. We are also happy to be among Debiopharm's partners in the antibody space," added Davis Farmer, MSM's Chairman.

Tajib A. Mirzabekov, Ph.D., President and CEO of MSM commented: "This is a very exciting transaction for MSM. We are working with a great partner, on a very exciting and valuable target and we have the chance to launch what may be the first novel biologic in Russia through our Russian subsidiary, Meprotek. It provides a substantial validation for our technology and our team to work with a company of Debiopharm's caliber. There is a great need in targeting of GPCRs with functionally active, high quality and potent human monoclonal antibodies."

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit:

About MSM Protein Technologies

MSM is a closely held drug discovery company based in Boston, MA. MSM is the leader in the discovery of antibodies targeting multispanning membrane proteins. The company applies its proprietary SIMPL (TM) platform and magnetic proteoliposome particles (MPLs) to display multispanners such as GPCRs in highly concentrated and purified form while retaining their native conformation and orientation thereby maximizing the probability of raising functional antibodies. MSM has demonstrated the ability to raise functional human antibodies against a number of GPCRs and other membrane proteins.

MSM was formed in 2005 on the basis of technology originally developed at the Dana Farber Cancer Institute by the company's founding scientist and subsequently licensed to MSM. Since then the Company has developed additional, novel technologies that provide greater power and sensitivity to the search for antibody drugs to multispanners.

For more information on MSM, please visit:

About G-protein Coupled Receptors (GPCRs)

GPCRs comprise a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. A G-protein is an intracellular membrane associated protein, responsible for activating the signalling cascade. GPCRs are coupled to G-proteins. GPCRs are the largest, most versatile group of membrane receptors and also the most pharmaceutically important, as more than 30% of the low-molecular weight drugs currently on the market are targeting this kind of receptors.

    Debiopharm S.A. Contact

    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    MSM Protein Technologies Contact
    Davis Farmer
    Tel: +1-781-321-3322
    Fax: +1-781-321-3360

    Additional Media Contacts

    In London
    Brian Hudspith
    Tel: +44(0)20-7379-5151

    In New York

    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
2. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
3. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
4. Japanese Cancer Association and Debiopharm Honour Japanese Research
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Debiopharm and EPFL Establish an Oncology Chair
7. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
8. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
9. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
10. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
11. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Researchers at the ... Institute for Brain Research at MIT have engineered changes ... cut down on "off-target" editing errors. The refined technique ... use of genome editing. Science , ... three of the approximately 1,400 amino acids that make ...
(Date:12/1/2015)... VIEW, Calif. , Dec. 1, 2015 /PRNewswire/ ... the Transformational Health program. This program addresses ways ... period of change. ... Logo - ... every aspect of healthcare, as well as the ...
(Date:12/1/2015)... ROSEVILLE, Minn. , Dec. 1, 2015  The ... the recipient of the 2015 Tekne Award in the ... th at the Minneapolis ... who have played a significant role in developing new ... people living around the world. Clostridium difficile ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):